{"name":"Orexo AB","slug":"orexo-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"BNX sublingual film","genericName":"BNX sublingual film","slug":"bnx-sublingual-film","indication":"Opioid use disorder maintenance treatment","status":"phase_3"},{"name":"BNX sublingual tablets","genericName":"BNX sublingual tablets","slug":"bnx-sublingual-tablets","indication":"Opioid use disorder maintenance treatment","status":"phase_3"},{"name":"Buprenorphine/naloxone sublingual tablets","genericName":"Buprenorphine/naloxone sublingual tablets","slug":"buprenorphine-naloxone-sublingual-tablets","indication":"Opioid use disorder maintenance treatment","status":"phase_3"},{"name":"Higher bioavailability BNX sublingual tablets","genericName":"Higher bioavailability BNX sublingual tablets","slug":"higher-bioavailability-bnx-sublingual-tablets","indication":"Opioid use disorder (maintenance treatment)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SL fentanyl","genericName":"SL fentanyl","slug":"sl-fentanyl","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"SL fentanyl","genericName":"SL fentanyl","slug":"sl-fentanyl","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BNX sublingual film","genericName":"BNX sublingual film","slug":"bnx-sublingual-film","phase":"phase_3","mechanism":"BNX is a buprenorphine sublingual film that binds to opioid receptors to provide analgesia and opioid dependence treatment.","indications":["Opioid use disorder maintenance treatment","Moderate to severe pain"],"catalyst":""},{"name":"BNX sublingual tablets","genericName":"BNX sublingual tablets","slug":"bnx-sublingual-tablets","phase":"phase_3","mechanism":"BNX is a buprenorphine sublingual tablet that binds to opioid receptors to provide analgesia and opioid dependence treatment.","indications":["Opioid use disorder maintenance treatment","Moderate to severe pain"],"catalyst":""},{"name":"Buprenorphine/naloxone sublingual tablets","genericName":"Buprenorphine/naloxone sublingual tablets","slug":"buprenorphine-naloxone-sublingual-tablets","phase":"phase_3","mechanism":"Buprenorphine acts as a partial mu-opioid receptor agonist while naloxone acts as a mu-opioid receptor antagonist, together providing opioid dependence treatment with abuse-deterrent properties.","indications":["Opioid use disorder maintenance treatment","Opioid dependence management"],"catalyst":""},{"name":"Higher bioavailability BNX sublingual tablets","genericName":"Higher bioavailability BNX sublingual tablets","slug":"higher-bioavailability-bnx-sublingual-tablets","phase":"marketed","mechanism":"BNX is a buprenorphine formulation designed to provide higher bioavailability through sublingual administration, enhancing opioid receptor partial agonism for pain and opioid use disorder treatment.","indications":["Opioid use disorder (maintenance treatment)","Moderate to severe pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxNdTJGYXpDZFd1Z3VIVmhsY2ZoSk9haTlENE15a3Zfd2pxMWdybTJNQm1BclY2eC1VR0FMa082UzJRZ1ZGT09HUVhraVRsbi1hejV3aGNmNFBkTDBpNWViYTI3ZHNQVTQ3Rm1sS1RtQWt4Rk5rbjRlQ1dHX2gzX3hIN1YzT2p4YTdUUjEzZGFoZlQxNEowUGIwblZSbmNRTGN6SnBGaGV5RnBvWWpFNWdtM2ZMYVI0UFFFNnh1NFhPOXJHeVJha2FsRVNsR2Y1aFhEYWpxZ1JGRG9mVUJlOEowMU15dFVLVldWY2wzaEg4ZHQwX2ZkRVJiV2ZUUU9wSnM4ZUZNVVpiaHhDNDh5TVFTeWF2bFlCcFQ1VXE2YU95UVRtbHc3VzNLUFBOS1FGSDlWTkoxWWNPUy1iSjVuN2hXTXRGTXY0cTVOWGc?oc=5","date":"2026-02-19","type":"pipeline","source":"TradingView","summary":"Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs - TradingView","headline":"Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1WLVBkVlQ0dVlVOTJUbzFnYW5IZVJWVnRCbFRzRVFic3d3QXI5X1lCRlZPazhkT3EyTkhxcEhrYUFSd3lLRDFkLVdYZ3BEb0NhS3R0MVJncGVuUWZpQUpqUWY0U1pVWGthbnM1VW5UYTVJNHFXXzlkMTlR?oc=5","date":"2026-01-16","type":"deal","source":"Drug Store News","summary":"Dexcel Pharma USA acquires U.S. rights to Zubsolv - Drug Store News","headline":"Dexcel Pharma USA acquires U.S. rights to Zubsolv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOR01rWl9Fb3hNcmdDMWppNmF2cUJBdEdNS3ljU1NGZkZtVU81TUZ2ZDJYZndnZy0yVnl0ck91R1V6UEVaREN1Z2E3QTNpcUpCRUNvTi1qUV9WMXAwQTNiSGRHRF9ZQ2otaEQybkZhcnNjOWZsRWV0ZGhUNWd0THFCRkQ4YUp6c25YRjQxYzBJNkRPbGxGY1NSdmlTNjFUaGNGMGczM0VR?oc=5","date":"2026-01-07","type":"deal","source":"PR Newswire","summary":"Dexcel Pharma USA Acquires US Rights to Zubsolv® - PR Newswire","headline":"Dexcel Pharma USA Acquires US Rights to Zubsolv®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOWjdBNm45NUMtOGlPVWFRWUhwazNROERXS1Uyczh3Mk0yTTJDeWJvWDg1a1ZLbVF3V21fNTlKdWFMekI5SHlMRWtfRml1TXNxOFBBTGFOWXpjR1Q2Y0daUklrYVBQV2pOQ1lnNWRBNGhGUGZFY3NjR09QTTFpSEI3NzhqWnhhVHFDVGZIYWt3?oc=5","date":"2025-09-30","type":"pipeline","source":"Contract Pharma","summary":"Orexo US Awarded $8M in Funding by BARDA - Contract Pharma","headline":"Orexo US Awarded $8M in Funding by BARDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPV0FYSzJZaHo1d29zcjVVRVFIN0pmcmZHSTlicUpmSXlDZEZIZ0s3QXlyUWpWSHN1TlVSWUNTUHVsWEttQ0N4Z0stLS1QbjNkRlFlYnR0VEh1VVFPaTZ0d1hXUWZmUVNqNko4RGFnSy1Pd2FXb2tmd1REY1M0QnZGaXdVTW9qeGt0bnFQUTNwejdrekhKVTRRbFJEdURrWk1JRTRKRFYyNFlJVVBzOS1jNXhiQXoxU3JNQmF4bUhRa0E?oc=5","date":"2024-07-17","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Orexo's opioid overdose drug - Reuters","headline":"US FDA declines to approve Orexo's opioid overdose drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQYnZ1M0piVUZHcVFvZDZTbjlfMmpUanB2Nmp2SThsTFNJTHpUel9Gd0J5TUxvTW55SUFYZ0o4SzZ2Ri01dnJWb3NOQ1dURkVkM2xvQlpkMG40aF9tTDZDYjI0bm1FT0hvU0x1elJRTXdYbGxZLXI0d0o3NUFZYUNpZ3ltQUthdWVTMXp4UnVVcy1yS0JJUHJodXNSXy01dS1HNXk4NFVB?oc=5","date":"2024-02-12","type":"trial","source":"Contract Pharma","summary":"Orexo AB Advances Exploratory Feasibility Study with Sobi - Contract Pharma","headline":"Orexo AB Advances Exploratory Feasibility Study with Sobi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNcWo1eHdUdHpUQkJkN0xiTmdLSmhBREhGNF9uYkx5QnY2SFUweGxOY2tCZ2tEajZhU2lyaDF3VzZ6d3RoVDNPbTlwSDNZZjExSDV4NUJPSGVHVndDelZZcG51Z2pnb1lBWnBNVDlPdW5oNGMwTlA1NHFSNXFlQ2tYYkpZUWpUd0xpWnB6NmZydVEzNjFZamc?oc=5","date":"2019-07-10","type":"deal","source":"Contract Pharma","summary":"Mundipharma Acquires Rights to Orexo’s Zubsolv - Contract Pharma","headline":"Mundipharma Acquires Rights to Orexo’s Zubsolv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOSDhaZWsxS0t6eS1pbnZwcWEybXFrdWpvelowRjM1UzJXam13NTUzWFBVSnI0QzRybS1acHVzY3JFRWNPS0VCREd2V0FCUWQwUWM1SVpUdm40TXBiZXlocUlmU1BiU0QwM3hkNEU0US1UX0xqN0dzN0ZZOC0xX3JlN2dsY0tvNHp1NmRTbDduc3RjRnhxVjMwQldBcFhSVjY5T3RDYjlsdjlyMWFWTE15ZFJB?oc=5","date":"2019-03-29","type":"patent","source":"Bloomberg.com","summary":"Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg.com","headline":"Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE1GQXRGbzJScWpSVmpMbFhHNFRJVnBoMjgxdEtyby1rMVBvRlB2dG50clZic0Z2azdsR1VSWWZEazdHTEVUMFd3WVhxcXlFRDBBU3QtZ3pzUHBKME0?oc=5","date":"2018-04-12","type":"pipeline","source":"TradingView","summary":"ORX Stock Price and Chart — OMXSTO:ORX - TradingView","headline":"ORX Stock Price and Chart — OMXSTO:ORX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5wb3BRMngtdHhNRUZyNGJmNS1zX1NwWDRpR1FMaV9NS1Q3c083eUMyZ1BObWhfQW1pazV0aHhKNXRYLURGMUFkdy1kQV9QbDBuTGpmUg?oc=5","date":"2017-05-13","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Moberg Pharma AB (publ) (MOB.ST) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Moberg Pharma AB (publ) (MOB.ST) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPc21HZXJaYXp1YnJySlB3UG5pd05YSUtYYzJ3dGFBWWJoZzZhdWNnYUZtdGdTcmtJY0hpSk1FZ201eEJjdlhKMTQtWGR5b2doLXpDR2dpMDFvMFZDTE1VSUJPVURxaDRvOXM4a201dUtxTHM4bkMtWWVtdk95c21XZk1IZm13d0JkY0RsOGZBak9HX0FzRU1CY2VBV0hzVzZoVDJn?oc=5","date":"2013-03-18","type":"pipeline","source":"Fierce Biotech","summary":"Abstral® by Orexo sells in the United States to Galena Biopharma, Inc. - Fierce Biotech","headline":"Abstral® by Orexo sells in the United States to Galena Biopharma, Inc.","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":2,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}